so close26 Oct 2009 10:55
CLOSE NOW - LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that the LiDCOrapid Monitor, the Company's tool for acute care fluid and drug management, has been chosen as the sole cardiac output monitoring system to be used in OPTIMISE, a government-supported multi-centre trial in the UK, which aims to improve surgical outcomes by optimising cardiovascular management. This trial is believed to be the largest of its type in the world to date and is therefore a significant validation of LiDCO's technology. ......Co-ordinated by Dr Rupert Pearse, consultant and senior lecturer in intensive care medicine at Barts and London NHS Trust, the study is supported by an £850,000 grant from the National Institute for Health Research.
Terry O'Brien, Chief Executive Officer of LiDCO, said: "We believe this will be the largest trial on improving outcomes in high-risk surgery conducted in the world to-date. We are delighted that the LIDCOrapid has been chosen to guide the administration of the fluids and heart drugs each patient will need both during the operation and the following six hours during post operative care. We are confident that OPTIMISE will prove to be a landmark trial inin the widespread adoption of surgical optimisation."
In a recent BBC interview about this trial, Dr Pearse stated: "This grant will expand research in the field of critical care and apply this approach to our clinical practice, in order to imp